Analyst Price Targets — RVMD
Latest News for RVMD
Revolution Medicines aims to replace chemotherapy with target treatments. Its positive Phase 3 findings could pave the way towards its regulatory approval.
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxonrasib, the company's investigational RAS(ON)…
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RVMD.
U.S. House Trading
No House trades found for RVMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.